Astrazeneca (AZN) Selling, General & Administrative (2009 - 2026)
Astrazeneca (AZN) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
SG&A (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
-2.86 Bn |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
2.93 Bn |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
6.03 Bn |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
3.58 Bn |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
2.70 Bn |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
1.60 Bn |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
1.45 Bn |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
2.96 Bn |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
1.62 Bn |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
-4.92 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
-4.92 Bn |
| Dec 31, 2025 |
-5.49 Bn |
| Sep 30, 2025 |
-5.09 Bn |
| Jun 30, 2025 |
-4.86 Bn |
| Mar 31, 2025 |
-4.49 Bn |
| Dec 31, 2024 |
-5.41 Bn |
| Sep 30, 2024 |
-5.14 Bn |
| Jun 30, 2024 |
-4.93 Bn |
| Mar 31, 2024 |
-4.50 Bn |
| Dec 31, 2023 |
-5.37 Bn |
| Sep 30, 2023 |
-4.80 Bn |
| Jun 30, 2023 |
-4.99 Bn |
| Mar 31, 2023 |
-4.06 Bn |
| Dec 31, 2022 |
-4.62 Bn |
| Sep 30, 2022 |
-4.28 Bn |
| Jun 30, 2022 |
-4.68 Bn |
| Mar 31, 2022 |
-4.84 Bn |
| Dec 31, 2021 |
-5.12 Bn |
| Sep 30, 2021 |
-4.09 Bn |
| Jun 30, 2021 |
-3.10 Bn |
